Mission Bio launches first-in-class single-cell genomics solid tumor solution on the Tapestri platform

0

Tapestri Solution for Solid Tumor Research offers enhanced CNV analysis capability, by

supplement to breast cancer and glioblastoma research panels

SOUTH SAN FRANCISCO, CA., March 29, 2022 /PRNewswire/ — Mission Bio, Inc.the pioneer of multi-omics and high-throughput single-cell DNA analysis, today launched the Tapestri Solution for Solid Tumor Research. This new end-to-end single-cell DNA sequencing workflow on the Tapestri platform includes a nuclear isolation preparation protocol, pre-designed research panels for breast cancer and glioblastoma multiforme, and an improved single-cell copy number (CNV) variation bioinformatics analysis tool. With these new capabilities, Mission Bio now offers coverage of solid tumors in addition to hematological cancers, where researchers regularly use Tapestri to probe tumor heterogeneity and exploit it for new understandings of clonal diversity and architecture. underlying disease progression, biomarkers and clinical practice.

(PRNewsfoto/Mission Bio)

Recent high profile research studies using personalized Tapestri tests for breast cancer, non-small cell lung cancer, colorectal cancerand melanoma showed the utility of high-resolution tools to better assess solid tumor heterogeneity and clonal evolution, which contribute to disease onset, progression and relapse. Next-generation mass sequencing methods are unable to provide the cell-by-cell mutational data needed to identify biological drivers of disease – they are limited to representing only population-level mean measures and lack clear data on clonal diversity.

Tapestri accurately measures DNA damage at the individual cellular level in thousands of cells at once, co-detecting single nucleotide variations (SNVs), indels and CNVs, definitively identifying variant zygosity and mutational co-occurrence, and detecting rare cell populations. Solid tumor researchers can now take advantage of a comprehensive workflow optimized for the Tapestri platform, including:

  • Assistance with sample preparation with improved nucleus isolation preparation protocol for fresh and fresh frozen samples

  • New research panels for breast cancer and glioblastoma, designed to include a carefully curated selection of hotspot genes, CNVs and chromosome arm aneuploidies associated with each respective disease. Additionally, customers can design custom panels that target anywhere in the human or mouse genome

  • Optimized CNV Bioinformatics Analysis Capabilities thanks to a new visualization tool (with Mission Bio’s Field Application Scientist team).

Overall, this total workflow solution can help the field both deepen our understanding of disease progression and develop more precise therapies.

The commercial launch of Mission Bio’s Tapestri solution for solid tumor research underscores the company’s continued commitment to enabling higher resolution cancer research more broadly with single-cell DNA sequencing. To promote best practices for single-cell DNA profiling of solid tumors, Mission Bio recently announced its first Center of Excellence at Memorial Sloan Kettering Cancer Center (MSKCC).

“The impressive results already achieved in our early work with solid tumor researchers have helped guide the development of these new workflows and underscore our commitment to providing unique and indispensable tools to solid tumor researchers. Just as Tapestri has been an invaluable tool for hematology researchers. , we are confident that our pair of research panels, novel preparation protocol, and enhanced bioinformatics analysis capabilities will demonstrate the platform’s value in solid tumors,” said Yan ZhangPhD, CEO of Mission Bio.

To learn more about Mission Bio and the Tapestri platform, please visit missionbio.com.

About Mission Bio
Mission Bio is a life sciences company accelerating discovery and treatment for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies. Mission Bio’s multi-omics approach improves time to market for new therapies, including innovative cell and gene therapies that open new pathways to health. Founded in 2014, Mission Bio has secured investments from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund and others.

The Company’s Tapestri platform gives researchers around the world the power to interrogate every molecule in a cell together, providing a comprehensive understanding of the activity of a single sample. Tapestri is the only commercial multi-omics platform capable of simultaneously analyzing DNA and proteins from the same sample at single-cell resolution. The Tapestri platform is used by customers at leading research centers, pharmaceutical companies and diagnostics companies around the world to develop treatments and eventually cures for cancer.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to historical facts should be considered forward-looking statements, including, without limitation, statements regarding our expectations regarding the transaction described above, including anticipated benefits, anticipated payments, future business and market opportunities, and anticipated growth resulting from the transaction; the potential, safety, efficacy and regulatory and clinical progress of our product candidates; our leadership position in the development of genetic drugs; and the adequacy of our cash and cash equivalents to fund our operations; These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements. expressed or implied by the forward-looking statements. statements, including but not limited to the following: we may not realize the anticipated benefits of working with Oxford Biomedica; the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur material losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the first step in our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; our product candidates may cause serious adverse side effects; the inability to maintain our collaborations, or the failure of such collaborations; our dependence on third parties; failure to obtain marketing authorization in the United States or abroad; current regulatory obligations; the effects of significant competition; adverse pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability claims; inability to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; intellectual property risks and significant costs resulting from operating as a public company. These and other important factors discussed under “Risk Factors” in our quarterly report on Form 10-Q for the quarter ended September 30, 2021 and our other filings with the Securities and Exchange Commission (“the SEC”) could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These forward-looking statements represent management’s estimates as of the date of this press release. Although we may choose to update these forward-looking statements at some time in the future, we disclaim any obligation to do so, even if subsequent events change our views.

Media Contacts
Consort Partners for Mission Bio
[email protected]

Quote

Quote

View original content to download multimedia: https://www.prnewswire.com/news-releases/mission-bio-launches-first-in-class-single-cell-genomics-solid-tumor-solution-on-tapestri -platform-301511732.html

SOURCE Mission Biography

Share.

Comments are closed.